Albumin-based nanodevices as drug carriers

dc.commentsCEB37809por
dc.contributor.authorLoureiro, Ana Isabel Sápor
dc.contributor.authorAzóia, Nuno G.por
dc.contributor.authorGomes, Andreia Cpor
dc.contributor.authorCavaco-Paulo, Arturpor
dc.date.accessioned2016-12-07T11:09:43Z
dc.date.issued2016
dc.date.updated2016-12-02T00:26:35Z
dc.description.abstractNanomedicine, the application of nanotechnology to medicine, is being increasingly used to improve and exploit the advantages of efficient drug delivery. Different nanodevices have been developed in recent years, among them protein-based nanoparticles which have gained considerable interest. Albumin is a versatile protein carrier with several characteristics that make it an ideal candidate for drug delivery, such as its availability, its biocompatibility, its biodegradability, and its lack of toxicity and immunogenicity. This review embodies an overview of different methods available for production of albumin-based nanoparticles, with focus on high-energy emulsification methods. A comparison between production by using sonication, which involves acoustic cavitation, and the high pressure homogenization method, where occurs hydrodynamic cavitation, is presented. Taking into account important properties of nanoparticles required for intravenous administration, the use of poloxamers, tri-block copolymer surfactants is discussed as it improves blood circulation time and bioavailability of nanoparticles. Thus, nanoparticles can be engineered to provide adequate features to therapeutic applications, in which can be included surface functionalization with targeting agents. Different albumin-based formulations and their therapeutic applications are presented in this review, with emphasis on applications in cancer therapy, where albumin-based strategies are promising for targeted drug delivery in innovative clinical strategies.por
dc.description.sponsorshipAna Loureiro (SFRH/BD/81479/2011) holds a PhD scholarship from Fundação para a Ciência e a Tecnologia (FCT). This work has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement NMP4-LA2009-228827 NANOFOL. This work was supported by FEDER through POFC - COMPETE and by Portuguese funds from FCT through the project PEst-OE/BIA/UI4050/2014 and by FCT I. P. through the strategic funding UID/BIA/04050/2013. The authors also thank the FCT Strategic Project of UID/BIO/04469/2013 unit.por
dc.distributioninternationalpor
dc.identifier.citationLoureiro, Ana; Azoia, Nuno G.; Gomes, Andreia C.; Cavaco-Paulo, Artur, Albumin-based nanodevices as drug carriers. Current Pharmaceutical Design, 22(10), 1371-1390, 2016por
dc.identifier.doi10.2174/1381612822666160125114900por
dc.identifier.issn1381-6128por
dc.identifier.pmid26806342por
dc.identifier.urihttps://hdl.handle.net/1822/43314
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherBentham Science Publisherspor
dc.relationinfo:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F81479%2F2011/PTpor
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/228827/EUpor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/135919/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147364/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147337/PTpor
dc.rightsclosedAccesspor
dc.subjectNanomedicinepor
dc.subjectAlbuminpor
dc.subjectNanoparticlespor
dc.subjectProduction methodspor
dc.subjectSpecific drug deliverypor
dc.subjectCancer therapypor
dc.subject.wosScience & Technologypor
dc.titleAlbumin-based nanodevices as drug carrierspor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationConferencePlaceUnited Arab Emirates
oaire.citationEndPage1390por
oaire.citationIssue10por
oaire.citationStartPage1371por
oaire.citationTitleCurrent Pharmaceutical Designpor
oaire.citationVolume22por
sdum.journalCurrent Pharmaceutical Designpor
sdum.publicationstatusinfo:eu-repo/semantics/publishedVersionpor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_37809_1.pdf
Tamanho:
3.99 MB
Formato:
Adobe Portable Document Format